Drug Profile
GSC 53
Latest Information Update: 05 Jun 2002
Price :
$50
*
At a glance
- Originator AVANT Immunotherapeutics
- Class Glycoconjugates; Trisaccharides
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypersensitivity; Transplant rejection
Most Recent Events
- 05 Jun 2002 Discontinued - Preclinical for Allergy in USA (unspecified route)
- 05 Jun 2002 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
- 30 May 2001 Profile reviewed but no significant changes made